A randomised controlled trial found that real-time (rtCGM) improved glycaemia in a predominantly Māori population of adults with insulin-requiring type 2 diabetes. The trial assigned 67 participants with HbA1c ≥64 mmol/mol (8.0%), who were using insulin ≥0.2 U/kg/day, to rtCGM or self-monitoring blood glucose (SMBG). A total of 54% of participants were Māori. The primary endpoint was time in the target glucose range (TIR; 3.9-10 mmol/L) during weeks 10-12. Mean TIR increased by 13% (95% CI 4.2 to 22%; p = 0.007) in the rtCGM group but did not change in the SMBG group. Baseline-adjusted between-group difference in TIR was 10.4% (95% CI -0.9 to 21.7; p = 0.07). Mean HbA1c decreased from baseline in both groups (p < 0.001 for both). No severe hypoglycaemic or ketoacidosis events occurred in either group.
